Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for lung cancer patients too frail for standard chemo

NCT ID NCT07392658

Recruiting now Disease control Sponsor: Fondazione Ricerca Traslazionale Source: ClinicalTrials.gov ↗

First seen Feb 06, 2026 · Last updated May 14, 2026 · Updated 9 times

Summary

This study tests a combination of the targeted drug amivantamab plus a single chemotherapy drug in people with advanced non-small cell lung cancer that has a specific EGFR mutation (exon20 insertion). Participants must not have had prior treatment and must be unable to receive standard platinum-based chemotherapy due to kidney problems, age, or other health issues. The goal is to see if this combination can shrink tumors and improve survival with manageable side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC NSCLC - NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • I.F.O. Istituti Fisioterapici Ospitalieri Istituto Nazionale Tumori "Regina Elena", Medical Oncology 2

    RECRUITING

    Roma, Roma (RM), 00144, Italy

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

METASTATIC NSCLC - NON-SMALL CELL LUNG CANCER